Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
ImmuCell Corporation is positioned for growth with its innovative product, First Defense, which protects calves from major pathogens, and its upcoming product, Re-Tain, which addresses subclinical mastitis in dairy cows. The company has...
— Substack
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on ImmuCell Corporation
ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves.
ImmuCell Corporation ($ICCC) is an animal health company focused on developing and commercializing preventative biological products, led by its flagship First Defense franchise that treats calf scours (severe neonatal diarrhea in dairy and beef calves). The manager's bullish...